Publications by authors named "M Fakhry Davids"
The anti-apoptotic protein myeloid cell leukemia-1 (Mcl-1) contributes to the pathophysiology of acute myeloid leukemia (AML) and certain B-cell malignancies. Tumor dependence on Mcl-1 is associated with resistance to venetoclax. Voruciclib, an oral cyclin-dependent kinase (CDK) inhibitor targeting CDK9, indirectly decreases Mcl-1 protein expression and synergizes with venetoclax in preclinical models.
View Article and Find Full Text PDFPurpose: The AMPLIFY trial recently established fixed-duration acalabrutinib, venetoclax, and obinutuzumab (AVO) as a new standard-of-care option for patients with previously untreated chronic lymphocytic leukemia (CLL) with wild-type ; however, due to the chemoimmunotherapy control arm, AMPLIFY excluded patients with high-risk aberration, for whom current standards of care are continuous Bruton tyrosine kinase inhibitor therapy or alternatively fixed-duration venetoclax-based doublets. AVO has not previously been evaluated in patients with CLL with aberration.
Methods: This investigator-sponsored, multicenter, phase II study enrolled patients with treatment-naïve CLL enriched for high-risk CLL, defined by aberration (ClinicalTrials.
Article Synopsis
- Maternal stress during the postpartum period affects the nutrient composition and microbiome of human milk (HM), potentially impacting early development and mental health outcomes for infants.
- A study involving high-stress (HS) and control groups analyzed HM microbiome changes, revealing distinct differences in bacterial composition, particularly showing HS mothers had altered levels of certain bacteria like reduced Streptococcus and increased Staphylococcus.
- The findings indicate a strong correlation between maternal stress and changes in the HM microbiome, suggesting these alterations could influence infant gut colonization and overall health, necessitating further research on their implications.
Chronic lymphocytic leukemia (CLL) patients have an increased risk of secondary cancers, along with predisposition to CLL in their relatives. We have previously identified germline ATM variants as associated with CLL risk; here, we present their impact on predisposition to secondary neoplasms in CLL patients and their relatives. Patients enrolled in our tissue bank who had germline ATM status available were mailed a questionnaire between April 2022 and May 2023.
View Article and Find Full Text PDF